A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

NCT03430063 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Advanced Non-Small Cell Lung Carcinoma

Interventions

DRUG: SDREGN2810
DRUG: SDREGN2810/ipi
DRUG: HDREGN2810

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]